{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:27Z","timestamp":1792190487587,"version":"4.4.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Fibromyalgia is a chronic disorder characterized by pain and psychological symptoms in adults. Several randomized controlled trials (RCTs) have shown the effectiveness and safety of low-dose naltrexone (LDN) in the treatment of fibromyalgia in variable small settings. Hence the need to conducted a meta-analysis to evaluate the overall effect and the strength of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>\n                      PUBMED, CENTRAL, and ClinicalTrials.gov were searched to retrieve RCTs comparing naltrexone with placebo in fibromyalgia patients for systematic review and meta-analysis. We conducted pairwise meta-analyses using DerSimonian and Laird random-effects model via RevMan 5.4. We reported dichotomous outcomes as relative risk (RR) and continuous outcomes as standardized mean difference (SMD) with 95% confidence intervals (CIs). Quality of included RCTs was assessed using revised Cochrane Risk of Bias Tool for RCTs (RoB 2.0). Heterogeneity was detected by Chi\n                      <jats:sup>2<\/jats:sup>\n                      and\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      values for each meta-analysis and if significant, sensitivity analysis was performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We included five RCTs in meta-analysis. Our results estimated that LDN is superior to placebo in alleviating pain both in primary (SMD \u22120.61; 95% CI \u22121.14,\u00a0\u22120.08) and sensitivity analysis (SMD \u22120.87; 95% CI \u22121.28,\u00a0\u22120.46) but not in raising mechanical pain threshold (SMD 0.24; 95% CI \u22120.09, 0.56) in fibromyalgia patients. Neither the primary (RR 1.68; 95% CI 0.84, 3.36) nor sensitivity analysis (RR 0.98; 95% CI 0.72, 1.34) could associate LDN use with the incidence of headache. The incidence of vivid dreams (RR 2.41; 95% CI 1.77, 3.28) was significantly higher in treatment group as compared to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>LDN is considered to be effective in the treatment of fibromyalgia. No serious adverse effects were reported in treatment group. There is need for more RCTs to support the evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000003203","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T19:54:05Z","timestamp":1743191645000},"page":"2928-2935","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of low-dose naltrexone (LDN) in fibromyalgia: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"87","author":[{"given":"Muhammad Hashir","family":"Nazir","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uswa","family":"Mehboob","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Farhan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Ajman University, Ajman, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirath","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Trinity Medical Sciences University School of Medicine, Ratho Mill Kingstown, Saint Vincent and Grenadines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleha","family":"Nazir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooba Ahmed","family":"Durrani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dubai Medical University, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Khafaja","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Ajman University, Ajman, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Sobhi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Ajman University, Ajman, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariyam","family":"Kuznetsova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Ajman University, Ajman, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Henry Ford Macomb Hospital, Clinton Township, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoola","family":"Awosika","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Illinois College of Medicine Peoria, Peoria, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"10.1038\/s41584\u2013020\u201300506\u2013w","DOI":"10.1038\/s41584-020-00506-w","article-title":"Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment","volume":"16","author":"Sarzi-Puttini","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.rbr.2016.10.004","article-title":"Prevalence of fibromyalgia: literature review update","volume":"57","author":"Marques","year":"2017","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/j.pain.0000000000001819","article-title":"A review of the incidence and risk factors for fibromyalgia and chronic widespread pain in population-based studies","volume":"161","author":"Creed","year":"2020","journal-title":"Pain"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/01.rhu.0000221817.46231.18","article-title":"The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th revision codes","volume":"12","author":"Weir","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"2016 revisions to the 2010\/2011 fibromyalgia diagnostic criteria","volume":"46","author":"Wolfe","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jpain.2018.10.008","article-title":"AAPT diagnostic criteria for fibromyalgia","volume":"20","author":"Arnold","year":"2019","journal-title":"The Journal of Pain"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ncprheum0245","article-title":"Cognitive behavioral therapy for fibromyalgia","volume":"2","author":"Bennett","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R9-20260805","first-page":"CD011336","article-title":"Aquatic exercise training for fibromyalgia","volume":"2014","author":"Bidonde","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20260805","first-page":"CD010884","article-title":"Resistance exercise training for fibromyalgia","volume":"2013","author":"Busch","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40199-019-00257-4","article-title":"Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial","volume":"27","author":"Bidari","year":"2019","journal-title":"Daru"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1001\/jama.292.19.2388","article-title":"Management of fibromyalgia syndrome","volume":"292","author":"Goldenberg","year":"2004","journal-title":"Jama"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/j.pain.0000000000000558","article-title":"Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial","volume":"157","author":"Gilron","year":"2016","journal-title":"Pain"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/medsci6040082","article-title":"Low-dose naltrexone (LDN)\u2014review of therapeutic utilization","volume":"6","author":"Toljan","year":"2018","journal-title":"Med Sci"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/biomedicines11041087","article-title":"Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: a fourteen-year, enterprise-wide retrospective analysis","volume":"11","author":"Driver","year":"2023","journal-title":"Biomedicines"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"189","DOI":"10.31128\/AJGP-09-22-6564","article-title":"Low-dose naltrexone in the treatment of fibromyalgia: a systematic review and narrative synthesis","volume":"52","author":"Aitcheson","year":"2023","journal-title":"Aust J Gen Pract"},{"key":"R17-20260805","doi-asserted-by":"crossref","first-page":"e15638","DOI":"10.1016\/j.heliyon.2023.e15638","article-title":"A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia","volume":"9","author":"Partridge","year":"2023","journal-title":"Heliyon"},{"key":"R18-20260805","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R21-20260805","first-page":"14898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed)"},{"key":"R22-20260805","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10741-019-09774-5","article-title":"Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials","volume":"24","author":"Fukuta","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R23-20260805","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R24-20260805","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R26-20260805","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1097\/PR9.0000000000001080","article-title":"Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study","volume":"8","author":"Bested","year":"2023","journal-title":"Pain Rep"},{"key":"R27-20260805","doi-asserted-by":"crossref","first-page":"A719","DOI":"10.1136\/annrheumdis-2013-eular.2126","article-title":"SAT0402 efficacy of naltrexone in the treatment of fibromyalgia: randomized controlled trial","volume":"72","author":"Abou-Raya","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R28-20260805","doi-asserted-by":"crossref","first-page":"e5180","DOI":"10.1371\/journal.pone.0005180","article-title":"Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology","volume":"4","author":"Younger","year":"2009","journal-title":"PLoS One"},{"key":"R29-20260805","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R30-20260805","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S2665-9913(23)00278-3","article-title":"Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial","volume":"6","author":"Due Bruun","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"R31-20260805","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"R32-20260805","first-page":"CD010410","article-title":"Low dose naltrexone for induction of remission in Crohn\u2019s disease","volume":"4","author":"Parker","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R33-20260805","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-018-1242-0","article-title":"Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis","volume":"17","author":"Bolton","year":"2019","journal-title":"BMC Med"},{"key":"R34-20260805","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00296-019-04251-6","article-title":"Role of inflammation in the pathogenesis and treatment of fibromyalgia","volume":"39","author":"Coskun Benlidayi","year":"2019","journal-title":"Rheumatol Int"},{"key":"R35-20260805","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.intimp.2018.05.020","article-title":"Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy","volume":"61","author":"Li","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"R36-20260805","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/phar.2086","article-title":"The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn\u2019s disease, and other chronic pain disorders","volume":"38","author":"Patten","year":"2018","journal-title":"Pharmacotherapy"},{"key":"R37-20260805","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R38-20260805","doi-asserted-by":"crossref","first-page":"e232502","DOI":"10.1136\/bcr-2019-232502","article-title":"Low-dose naltrexone as a treatment for chronic fatigue syndrome","volume":"13","author":"Bolton","year":"2020","journal-title":"BMJ Case Rep"},{"key":"R39-20260805","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1097\/JS9.0000000000001948","article-title":"Evolving trends in stem cell therapy: an emerging and promising approach against various diseases","volume":"110","author":"Abusalah","year":"2024","journal-title":"Int J Surg"},{"key":"R40-20260805","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2147\/JPR.S395457","article-title":"The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: a systematic review","volume":"16","author":"Yang","year":"2023","journal-title":"Jpr"},{"key":"R41-20260805","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/pm\/pnaa001","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose\u2013response relationships","volume":"21","author":"Bruun-Plesner","year":"2020","journal-title":"Pain Med"},{"key":"R42-20260805","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","article-title":"Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate","volume":"113","author":"Palpacuer","year":"2018","journal-title":"Addiction"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000003203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:03:00Z","timestamp":1785931380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000003203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003203","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"2024-10-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}